Clinical trial
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu…
NCT00433095 · Ludwig-Maximilians - University of Munich, Other · Completed
Key facts
| NCT number | NCT00433095 |
|---|---|
| Title | Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer |
| Lead sponsor | Ludwig-Maximilians - University of Munich, Other |
| Collaborators | Pierre Fabre Laboratories Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma Breast Stage IV |
| Intervention type | Drug |
| Interventions | Navelbine, Herceptin, Navelbine (oraly) |
| First posted | Feb 9, 2007 |
| Last update posted | Mar 14, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: